SCHEMBL5234643

SCHEMBL5234643

Cc1csc(Cl)c1NC(=O)C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 2/20 0.42
PDK2 Q15119 2/20 0.42
PDK3 Q15120 2/20 0.42
PDK4 Q16654 2/20 0.42
KMT2A Q03164 1/20 0.38
HTT P42858 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.35
CHUK O15111 1/20 0.34
MAPT P10636 3/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
RAB9A P51151 1/20 0.33
CA2 P00918 1/20 0.33
SIK1 P57059 1/20 0.33
SIK2 Q9H0K1 1/20 0.33
SIK3 Q9Y2K2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5237466 0.86 PDK1 (0.38) PDK1PDK2PDK3PDK4KMT2A
SCHEMBL4610178 0.84 PDK1 (0.62) PDK1PDK2PDK3PDK4
SCHEMBL21875055 0.80 KMT2A (0.45) KMT2AHTTL3MBTL1MAPTCYP1A2
SCHEMBL3715260 0.79 ALDH1A1 (0.52) PDK1PDK2PDK3PDK4KMT2A
SCHEMBL613613 0.76 MAPT (0.58) KMT2AHTTMAPTCYP1A2CYP2C19
SCHEMBL25095439 0.73 PDK1 (0.55) PDK1PDK2PDK3PDK4KMT2A
SCHEMBL3040193 0.72 KMT2A (0.38) KMT2AMAPTCYP1A2CYP2C19ALDH1A1
SCHEMBL8389121 0.70 ANO1 (0.40) L3MBTL1MAPTCA2ANO1
SCHEMBL10855357 0.70 DRD2 (0.41) KMT2AHTTMAPTCYP1A2ALDH1A1
SCHEMBL26575330 0.69 ALDH1A1 (0.55) KMT2AHTTL3MBTL1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1664058-B1 SUBSTITUTED THIENOIMIDAZOLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT OR DIAGNOSTIC AND MEDICAMENTS COMPRISING THE SAME SANOFI AVENTIS DEUTSCHLAND (DE) 2007-11-14 EP disclosed
US-7179830-B2 Substituted thienoimidazoles useful for disease treatment and prevention SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-02-20 US disclosed
EP-1664058-A1 SUBSTITUTED THIENOIMIDAZOLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT OR DIAGNOSTIC AND MEDICAMENTS COMPRISING THE SAME Sanofi-Aventis Deutschland GmbH (DE) 2006-06-07 EP disclosed
US-20050075385-A1 Substituted thienoimidazoles useful for disease treatment and prevention AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-04-07 US disclosed
WO-2005026173-A1 SUBSTITUTED THIENOIMIDAZOLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT OR DIAGNOSTIC AND MEDICAMENTS COMPRISING THE SAME SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075385-A1 Substituted thienoimidazoles useful for disease treatment and prevention TPMT, TYMS, SLC19A2 PDK1 1767/4885PDK2 981/4885PDK3 1824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.